Stephen Harrison leads the Surfers through a review of FGF-21s and other exciting drug development news.
Stephen Harrison starts this week's discussion reviewing the recent announcement of a promising Phase 1b/2a study for 89bio-100 (link to slide deck below), an FGF-21 agent that demonstrated significant reductions on liver fat and had positive effects on other metabolic measures. The discussion broadened to address an array of issues: other agents in development; changing (higher) expectations for how these agents will affect PDFF and possibly fibrosis; possible directions for combination therapy; and the five clinical values that collectively tell us the impact new medications can have on overall liver and metabolic health. One Surfer described this as a "brilliant 20-minute review."
89bio-slide deck: http://bit.ly/89bio-report